Literature DB >> 24780500

Impact of anatomical and functional severity of coronary atherosclerotic plaques on the transmural perfusion gradient: a [15O]H2O PET study.

Ibrahim Danad1, Pieter G Raijmakers2, Hendrik J Harms2, Martijn W Heymans3, Niels van Royen1, Mark Lubberink4, Ronald Boellaard2, Albert C van Rossum1, Adriaan A Lammertsma2, Paul Knaapen5.   

Abstract

BACKGROUND: Myocardial ischaemia occurs principally in the subendocardial layer, whereas conventional myocardial perfusion imaging provides no information on the transmural myocardial blood flow (MBF) distribution. Subendocardial perfusion measurements and quantification of the transmural perfusion gradient (TPG) could be more sensitive and specific for the detection of coronary artery disease (CAD). The current study aimed to determine the impact of lesion severity as assessed by the fractional flow reserve (FFR) on subendocardial perfusion and the TPG using [(15)O]H2O positron emission tomography (PET) imaging in patients evaluated for CAD. METHODS AND
RESULTS: Sixty-six patients with anginal chest pain were prospectively enrolled and underwent [(15)O]H2O myocardial perfusion PET imaging. Subsequently, invasive coronary angiography was performed and FFR obtained in all coronary arteries irrespective of the PET imaging results. Thirty (45%) patients were diagnosed with significant CAD (i.e. FFR ≤0.80), whereas on a per vessel analysis (n = 198), 53 (27%) displayed a positive FFR. Transmural hyperaemic MBF decreased significantly from 3.09 ± 1.16 to 1.67 ± 0.57 mL min(-1) g(-1) (P < 0.001) in non-ischaemic and ischaemic myocardium, respectively. The TPG decreased during hyperaemia when compared with baseline (1.20 ± 0.14 vs. 0.94 ± 0.17, P < 0.001), and was lower in arteries with a positive FFR (0.97 ± 0.16 vs. 0.88 ± 0.18, P < 0.01). A TPG threshold of 0.94 yielded an accuracy to detect CAD of 59%, which was inferior to transmural MBF with an optimal cutoff of 2.20 mL min(-1) g(-1) and an accuracy of 85% (P < 0.001). Diagnostic accuracy of subendocardial perfusion measurements was comparable with transmural MBF (83 vs. 85%, respectively, P = NS).
CONCLUSION: Cardiac [(15)O]H2O PET imaging is able to distinguish subendocardial from subepicardial perfusion in the myocardium of normal dimensions. Hyperaemic TPG is significantly lower in ischaemic myocardium. This technique can potentially be employed to study subendocardial perfusion impairment in more detail. However, the diagnostic accuracy of subendocardial hyperaemic perfusion and TPG appears to be limited compared with quantitative transmural MBF, warranting further study. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Coronary artery disease; Fractional flow reserve; Myocardial perfusion; Positron emission tomography; Transmural perfusion gradient

Mesh:

Substances:

Year:  2014        PMID: 24780500     DOI: 10.1093/eurheartj/ehu170

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  20 in total

1.  New frontiers for cardiac PET: looking beyond mean transmural myocardial quantification.

Authors:  Doumit Daou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-06       Impact factor: 9.236

2.  Myocardial blood flow: Putting it into clinical perspective.

Authors:  Thomas Hellmut Schindler
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

Review 3.  Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).

Authors:  Roberto Sciagrà; Alessandro Passeri; Jan Bucerius; Hein J Verberne; Riemer H J A Slart; Oliver Lindner; Alessia Gimelli; Fabien Hyafil; Denis Agostini; Christopher Übleis; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-05       Impact factor: 9.236

Review 4.  Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease.

Authors:  Lauren A Baldassarre; Subha V Raman; James K Min; Jennifer H Mieres; Martha Gulati; Nanette K Wenger; Thomas H Marwick; Chiara Bucciarelli-Ducci; C Noel Bairey Merz; Dipti Itchhaporia; Keith C Ferdinand; Carl J Pepine; Mary Norine Walsh; Jagat Narula; Leslee J Shaw
Journal:  JACC Cardiovasc Imaging       Date:  2016-04

Review 5.  Quantification of PET Myocardial Blood Flow.

Authors:  Matthieu Pelletier-Galarneau; Patrick Martineau; Georges El Fakhri
Journal:  Curr Cardiol Rep       Date:  2019-02-28       Impact factor: 2.931

6.  Advances in imaging instrumentation for nuclear cardiology.

Authors:  Jae Sung Lee; Gil Kovalski; Tali Sharir; Dong Soo Lee
Journal:  J Nucl Cardiol       Date:  2017-07-17       Impact factor: 5.952

7.  Radionuclide imaging of subendocardial ischaemia: an insight into coronary pathophysiology or a technical artefact?

Authors:  Gianmario Sambuceti; Silvia Morbelli; Alessandro Bellini; Cecilia Marini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

8.  Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy.

Authors:  Roberto Sciagrà; Alessandro Passeri; Fabrizio Cipollini; Helga Castagnoli; Iacopo Olivotto; Cyrill Burger; Franco Cecchi; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

Review 9.  Coronary circulation: Pressure/flow parameters for assessment of ischemic heart disease.

Authors:  Henry Gewirtz
Journal:  J Nucl Cardiol       Date:  2018-04-10       Impact factor: 5.952

10.  PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients.

Authors:  Ines Valenta; Alexander Antoniou; Wael Marashdeh; Thorsten Leucker; Edward Kasper; Steven R Jones; Robert F Dannals; Lilja Solnes; Martin G Pomper; Thomas H Schindler
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2017-05-01       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.